BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 30, 2015
View Archived Issues
Serina initiates phase I trial of SER-214 in patients with Parkinson's disease
Read More
Valor initiates first-in-human study of IGN-002 for NHL
Read More
Rovalpituzumab tesirine from Stemcentrx receives FDA orphan drug designation
Read More
Identification of CSF biomarkers for atypical parkinsonian syndromes
Read More
Novel preclinical model for cancer cachexia
Read More
Agios Pharmaceuticals starts phase I trial of pyruvate kinase deficiency candidate
Read More
Bayer plans phase I trial of BAY-1251152 in patients with advanced cancers
Read More
Aimmune Therapeutics moves peanut allergy therapeutic AR-101 into phase III
Read More
City of Hope discloses SENP inhibitors that prevent HIV genome integration
Read More
Amarantus requests rare pediatric disease and orphan drug designations
Read More
ADCT-402 shows antitumor activity against CD19-expressing B-cell malignancies
Read More
Midatech Pharma completes acquisition of Zuplenz
Read More
Vitae initiates proof-of-concept study of VTP-38543 in atopic dermatitis
Read More
Novel reversible bromodomain inhibitor shows promise for AML
Read More
Novel BET bromodomain inhibitor from Epigenetix a potential clinical candidate
Read More
Entospletinib is well tolerated in iNHL patients
Read More
Nanjing Sanhome Pharmaceutical patents EGFR inhibitors
Read More
French scientists describe GPBAR1 agonists
Read More
Kyoto Pharmaceutical Industries reports napabucasin prodrugs
Read More
Bristol-Myers Squibb presents nAChR alpha7 agonists
Read More
Adamed develops p53-MDM2 interaction inhibitors
Read More
Takeda Pharmaceutical divulges muscarinic M1 PAMs
Read More
Shionogi reports development of antifungal agents
Read More